Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK3532795 is an orally active inhibitor of HIV-1 maturation. GSK3532795 combines broad coverage of polymorphic viruses (EC50: 15 nM toward a panel of common polymorphisms representative of 96.5% HIV-1 subtype B virus) with a favorable pharmacokinetic profile in preclinical species.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
100 mg | Inquiry | Inquiry | |
500 mg | Inquiry | Inquiry |
Description | GSK3532795 is an orally active inhibitor of HIV-1 maturation. GSK3532795 combines broad coverage of polymorphic viruses (EC50: 15 nM toward a panel of common polymorphisms representative of 96.5% HIV-1 subtype B virus) with a favorable pharmacokinetic profile in preclinical species. |
Synonyms | BMS 955176, GSK-3532795, BMS955176, BMS-955176, GSK3532795 |
Molecular Weight | 781.06 |
Formula | C44H64N2O8S |
CAS No. | 2097784-79-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BMS-955176 TFA 2097784-79-5 BMS 955176 GSK-3532795 BMS955176 TFA BMS955176 GSK 3532795 BMS-955176 GSK3532795 BMS 955176 TFA inhibitor inhibit